EUVIMEDEUVIMED entdecken
Open Access

1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies

Bahadır Bülbül, Necla Kulabaş, Merve Gürboğa, Ozlem Bingöl Ozakpınar, Ümmühan Çakmak, Fulya Öz Tuncay, Yakup Kolcuoğlu, Mohit Agrawal, Mujeeb Khan, İlkay Küçükgüzel

Chemistry & Biodiversity · 2026

DOI: 10.1002/cbdv.202503299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Bahadır Bülbül und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp Campus, Düzce, Türkiye. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, ErbB Receptors, Acetamides. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of novel 1,2,4‐triazole‐acetamide derivatives was synthesized and evaluated for anticancer and hEGFR inhibitory activity. The compounds were obtained via multistep synthesis and characterized by spectroscopic methods. Cytotoxicity was tested against PC‐3, MCF‐7, A549, and K562 cell lines. Compounds 18 , 19 , and especially 24 showed notable antiproliferative effects, with compound 24 exhibiting higher selectivity and potency than gefitinib. It also induced apoptosis and inhibited migration in A549 and PC‐3 cells, while selectively promoting invasion in PC‐3, suggesting EMT‐related behavior. In vitro kinase assays revealed compound 20 as the most potent hEGFR inhibitor (IC 50 = 43.8 ± 1.3 nM). Molecular docking and 200 ns molecular dynamics simulations confirmed its stable interaction with EGFR, particularly involving Cys797. These findings highlight compounds 20 and 24 as promising candidates for further development as EGFR‐targeted anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAntineoplastic AgentsErbB ReceptorsAcetamidesProtein Kinase InhibitorsHumansCell ProliferationStructure-Activity RelationshipApoptosisDrug Screening Assays, AntitumorMolecular Docking SimulationCell Line, TumorMolecular StructureMolecular Dynamics SimulationDose-Response Relationship, Drug

Stichwörter der Autor:innen

1,2,4‐triazolesapoptosiscancerhEGFR inhibitorsmolecular dynamics

Substanzen

TriazolesAntineoplastic AgentsErbB ReceptorsAcetamidesProtein Kinase Inhibitors1,2,4-triazoleacetamideEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp Campus, Düzce, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
  • Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
  • Department of Chemistry, Faculty of Science, Karadeniz Technical University, Trabzon, Türkiye.
  • School of Medical & Allied Sciences, K. R. Mangalam University, Gurugram, India.
  • Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.

Zitieren

APA

Bülbül, B., Kulabaş, N., Gürboğa, M., Ozakpınar, O. B., Çakmak, Ü., Tuncay, F. Ö., Kolcuoğlu, Y., Agrawal, M., Khan, M., & Küçükgüzel, İ. (2026). 1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202503299

Vancouver

Bülbül B, Kulabaş N, Gürboğa M, Ozakpınar OB, Çakmak Ü, Tuncay FÖ, et al. 1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202503299

BibTeX
@article{Blbl2026,
  author = {Bülbül, Bahadır and Kulabaş, Necla and Gürboğa, Merve and Ozakpınar, Ozlem Bingöl and Çakmak, Ümmühan and Tuncay, Fulya Öz and Kolcuoğlu, Yakup and Agrawal, Mohit and Khan, Mujeeb and Küçükgüzel, İlkay},
  title = {1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  doi = {10.1002/cbdv.202503299}
}
Kostenlos starten →